Palbociclib (PD-0332991) HCl

Name: Palbociclib (PD-0332991) HCl
Brand: Selleck Chemicals
SKU: S1116
Rating: 5 (155 reviews)

For research use only. Not for use in humans.

Licensed by Pfizer Catalog No.S1116

155 publications

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Selleck's Palbociclib (PD-0332991) HCl has been cited by 155 publications

Cell, 2019, 176(5):1083-1097

PubMed: 30739799 ( click the link to review the publication )

Nat Med, 2019, 25(2):292-300

PubMed: 30664779 ( click the link to review the publication )

Cancer Discov, 2019, 10.1158/2159-8290.CD-18-0830

PubMed: 31594766 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2018, 553(7686):91-95

PubMed: 29160310 ( click the link to review the publication )

Cell, 2018, 174(5):1127-1142

PubMed: 30078706 ( click the link to review the publication )

Cancer Discov, 2017, 7(10):1168-1183

PubMed: 28801307 ( click the link to review the publication )

Cell Stem Cell, 2017, 20(2):233-246

PubMed: 27989769 ( click the link to review the publication )

Cell Stem Cell, 2017, 21(4):489-501

PubMed: 28965767 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Immunol, 2017, 18(3):293-302

PubMed: 28092373 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 27(1):92-104

PubMed: 31925410 ( click the link to review the publication )

Nat Commun, 2020, 11(1):71

PubMed: 31900415 ( click the link to review the publication )

Gut, 2019, 68(2):207-217

PubMed: 29703791 ( click the link to review the publication )

Nat Microbiol, 2019, 4(12):2260-2272

PubMed: 31548682 ( click the link to review the publication )

Mol Cell, 2019, 76(4):562-573

PubMed: 31543423 ( click the link to review the publication )

Mol Cell, 2019, 73(1):22-35.e6

PubMed: 30527665 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1373

PubMed: 30914635 ( click the link to review the publication )

Nat Commun, 2019, 10(1):557

PubMed: 30718506 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(8):3921-3936

PubMed: 30805632 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2769

PubMed: 30692100 ( click the link to review the publication )

PLoS Biol, 2019, 17(3):e3000178

PubMed: 30865623 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2466-2479

PubMed: 30940663 ( click the link to review the publication )
Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Cell Rep, 2019, 26(10):2667-2680

PubMed: 30840889 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.119.232603

PubMed: 31481582 ( click the link to review the publication )

Oncogene, 2019, 38(20):3886-3902

PubMed: 30692638 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Cancers (Basel), 2019, 11(5)

PubMed: 31100952 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):271

PubMed: 30894510 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):376

PubMed: 31092814 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(10)

PubMed: 31590445 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(2):300-306

PubMed: 30595531 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):771-779

PubMed: 30837298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0162

PubMed: 31395685 ( click the link to review the publication )

Mol Oncol, 2019, 13(8):1778-1794

PubMed: 31180176 ( click the link to review the publication )

Mol Neurobiol, 2019, 56(1):465-489

PubMed: 29721855 ( click the link to review the publication )

Eur J Med Chem, 2019, 165:115-132

PubMed: 30665142 ( click the link to review the publication )

Oncogenesis, 2019, 8(7):38

PubMed: 31209198 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

Biochem Pharmacol, 2019, 163:133-141

PubMed: 30772267 ( click the link to review the publication )

J Transl Med, 2019, 17(1):245

PubMed: 31358010 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13405

PubMed: 31527634 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5912

PubMed: 30976015 ( click the link to review the publication )
Sci Rep, 2019, 9(1):13696

PubMed: 31548560 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29249

PubMed: 31264276 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1685289

PubMed: 31747859 ( click the link to review the publication )

Exp Cell Res, 2019, 10.1016/j.yexcr.2019.111782

PubMed: 31857114 ( click the link to review the publication )

Am J Transl Res, 2019, 11(6):3481-3489

PubMed: 31312360 ( click the link to review the publication )

Transl Oncol, 2019, 12(1):116-121

PubMed: 30290287 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0223555

PubMed: 31600301 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(4):967-973

PubMed: 31005255 ( click the link to review the publication )

Leuk Res, 2019, 78:3-11

PubMed: 30641417 ( click the link to review the publication )

Oncol Lett, 2019, 17(1):1153-1159

PubMed: 30655877 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:22

PubMed: 31372497 ( click the link to review the publication )

NPJ Precis Oncol, 2019, 03:18

PubMed: 31341951 ( click the link to review the publication )

Haematologica, 2019, 104(2):347-359

PubMed: 30262555 ( click the link to review the publication )

Oncotarget, 2019, 10(47):4907-4918

PubMed: 31448056 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Gut, 2018, 10.1136/gutjnl-2017-314544

PubMed: 29884612 ( click the link to review the publication )

Mol Cell, 2018, 71(2):332-342

PubMed: 30017584 ( click the link to review the publication )

Mol Cell, 2018, 71(4):592-605

PubMed: 30057199 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(12):6188-6205

PubMed: 29873780 ( click the link to review the publication )

Autophagy, 2018, 14(4):637-653

PubMed: 29368982 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3994-4005

PubMed: 29716919 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-3094

PubMed: 30538112 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4360-4369

PubMed: 29844123 ( click the link to review the publication )
Cell Rep, 2018, 24(5):1105-1112.e5

PubMed: 30067968 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):112

PubMed: 30180865 ( click the link to review the publication )

Oncogene, 2018, 37(37):5066-5078

PubMed: 29789718 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):446

PubMed: 29670090 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):897-907

PubMed: 29483214 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2622-2632

PubMed: 30282811 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(1):183-191

PubMed: 29416931 ( click the link to review the publication )

Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582

PubMed: 29452249 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:5785-5798

PubMed: 30510448 ( click the link to review the publication )

Cell Signal, 2018, 44:1-9

PubMed: 29284139 ( click the link to review the publication )

J Orthop Res, 2018, 36(6):1581-1589

PubMed: 29194728 ( click the link to review the publication )

Cell Cycle, 2018, 17(11):1329-1344

PubMed: 30037299 ( click the link to review the publication )

Cell Cycle, 2018, 17(14):1784-1796

PubMed: 29995568 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):424-430

PubMed: 29477843 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 102(5):1569-1576

PubMed: 30056081 ( click the link to review the publication )

Oncotarget, 2018, 9(77):34567-34581

PubMed: 30349650 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2018, 21(5):375-382

PubMed: 29764587 ( click the link to review the publication )

Oncotarget, 2018, 9(102):37753-37765

PubMed: 30701029 ( click the link to review the publication )

JCI Insight, 2018, 3(16)

PubMed: 30135308 ( click the link to review the publication )

Cell, 2018, 10.1016/j.cell.2018.11.011

PubMed: 30580964 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(9):1061-1070

PubMed: 28759028 ( click the link to review the publication )

Mol Cell, 2017, 68(6):1134-1146

PubMed: 29225033 ( click the link to review the publication )

Nat Commun, 2017, 8(1):607

PubMed: 28928360 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1193

PubMed: 29084956 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1995

PubMed: 29222471 ( click the link to review the publication )

Nat Commun, 2017, 8(1):241

PubMed: 28808226 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1415-1433

PubMed: 28778953 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6958-6968

PubMed: 28814434 ( click the link to review the publication )

Dev Cell, 2017, 43(4):449-462

PubMed: 29103955 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.26957

PubMed: 29889021 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):123

PubMed: 28629371 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(15):2427-2443

PubMed: 28444744 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1942-1953

PubMed: 28566433 ( click the link to review the publication )

Cell Oncol (Dordr), 2017, 40(3):209-218

PubMed: 28243976 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(3):676-688

PubMed: 27338091 ( click the link to review the publication )

Protein Sci, 2017, 26(4):870-879

PubMed: 28168755 ( click the link to review the publication )

Oncotarget, 2017, 8(63):107206-107222

PubMed: 29291023 ( click the link to review the publication )

Oncotarget, 2017, 8(56):95116-95134

PubMed: 29221116 ( click the link to review the publication )

Oncotarget, 2017, 8(34):55848-55862

PubMed: 28915557 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47239-47249

PubMed: 28525384 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:11581

PubMed: 27181366 ( click the link to review the publication )

Nat Commun, 2016, 7:12748

PubMed: 27599659 ( click the link to review the publication )

Nat Commun, 2016, 7:11302

PubMed: 27066737 ( click the link to review the publication )

Nat Commun, 2016, 7:11987

PubMed: 27329820 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(1):122-33

PubMed: 26728409 ( click the link to review the publication )
Cell Mol Life Sci, 2016, 73(4):883-900

PubMed: 26346493 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2486-2497

PubMed: 27507850 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(10):3203-3219

PubMed: 27486199 ( click the link to review the publication )

J Cancer, 2016, 7(8):947-56

PubMed: 27313785 ( click the link to review the publication )

J Immunol, 2016, 197(7):2673-85

PubMed: 27566829 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(26):39595-39608

PubMed: 27167191 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51163-51173

PubMed: 27323399 ( click the link to review the publication )

Oncotarget, 2016, 7(43):69111-69123

PubMed: 27564114 ( click the link to review the publication )

J Natl Cancer Inst, 2015, 108(6):djv406

PubMed: 26719346 ( click the link to review the publication )

J Exp Med, 2015, 212(6):953-70

PubMed: 26008897 ( click the link to review the publication )

J Cell Biol, 2015, 210(7):1257-68

PubMed: 26416968 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:76

PubMed: 26225123 ( click the link to review the publication )

Anticancer Res, 2015, 35(12):6623-32

PubMed: 26637878 ( click the link to review the publication )

Data Brief, 2015, 5:429-33

PubMed: 26958605 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):662-74

PubMed: 24362465 ( click the link to review the publication )

AIDS, 2014, 28(15):2213-22

PubMed: 25036183 ( click the link to review the publication )

FEBS J, 2014, 281(18):4179-94

PubMed: 24823279 ( click the link to review the publication )

BMC Cancer, 2014, 14:32

PubMed: 24444383 ( click the link to review the publication )

Oncol Lett, 2014, 7(5):1673-1678

PubMed: 24765199 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Universidade de Lisboa, 2014, Matias

PubMed: ( click the link to review the publication )

Cell Death Differ, 2013, 20(9):1241-9

PubMed: 23852369 ( click the link to review the publication )
Int J Cancer, 2013, 133(10):2341-50

PubMed: 23640782 ( click the link to review the publication )

Pharmacogenomics J, 2013, 13(1):94-104

PubMed: 22083351 ( click the link to review the publication )

Cell Cycle, 2013, 12(12):1892-900

PubMed: 23676220 ( click the link to review the publication )

Cell Cycle, 2013, 12(15):2384-94

PubMed: 23839043 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(17):4612-20

PubMed: 22761470 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2012, 26(2):236-46

PubMed: 23279822 ( click the link to review the publication )

Am J Cancer Res, 2012, 2(6):726-35

PubMed: 23226618 ( click the link to review the publication )

Cell Cycle, 2012, 11(19):3599-610

PubMed: 22935696 ( click the link to review the publication )

PLoS One, 2012, 7(12):e51847

PubMed: 23300567 ( click the link to review the publication )

georgetown university, 2012, georgetown university

PubMed: ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(20):8414-9

PubMed: 21536883 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

Features

Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).

Targets

CDK4/CyclinD3 ^[1] (Cell-free assay)	CDK4/CyclinD1 ^[1] (Cell-free assay)	CDK6/CyclinD2 ^[1] (Cell-free assay)
9 nM	11 nM	15 nM

In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser⁷⁸⁰. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. ^[1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. ^[2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. ^[3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
MOLM13	MV\LbY5ie2ViQYPzZZk>		MlnrNlQhcA>?		NFnKfHRKdmirYnn0bY9vKG:oIFPET\|Qh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR\|UxKG:oIECuNFAzKM7:TR?=	MWmyOFY1OTFyMx?=
COLO205	NUD4W21tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mk\wO\|IhcA>?		NEjFSIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt\|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEO2JO69VQ>?	Mn3lNlQ3PDFzMEO=
U937	NF\aW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVTMTGhEPzJiaB?=		MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN	M{PZT\|I1PjRzMUCz
MOLM13	M1vmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1rFd\|czKGh?		M{nhSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIhiemKxcnnu[{BHVFR\|IFnUSEBufXSjboSgZZN{\XO\|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB7NjFOwG0>	MUWyOFY1OTFyMx?=
MOLM13	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVv1[\|ZmPzJiaB?=		NFXZO5hCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JJNwemGoZX7pZk1z\XOrc4ThcpQhcHWvYX6gUW9NVTF\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnuZ49zeG:{YYTpc44hd2ZiW{PIYZRpgW2rZHnu[UBqdnSxIFTORUB4cXSqIFnDOVAhd2ZiMD6wPVYh\|ryP	NVT6Z4xYOjR4NEGxNFM>
MDA-MB-435	M2LZTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYKyOEBp		NV;3V5dVUUN3ME2wMlE3KM7:TR?=	MWGxOVgxOTh\|MR?=
K562	NH;4botEgXSxdH;4bYMhSXO\|YYm=		M1HH[\|k3KGh?	MX3EUXNQ	MofTTWM2OD1{IN88US=>	NV3UTmM6OjR2MUe1OlY>
DU145	NIDjZ4ZEgXSxdH;4bYMhSXO\|YYm=		NW[x[3RHQTZiaB?=	NUXBNoVXTE2VTx?=	NXOwPVl2UUN3ME23MlUh\|ryP	M1j5elI1PDF5NU[2
MDA-MB-231	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fJWVEh\|ryP	MXqyOEBp	MoPLSG1UVw>?	M4WxcmNmdGxiY4njcIUh[XK{ZYP0JIF{e2W\|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=>	NYK1fFlDOjR2MUe1OlY>
MCF7	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml6yNUDPxE1?	Mnz6NlQhcA>?	MV7EUXNQ	NFzm[mpE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U>	NX\zTmY3OjR2MUe1OlY>
MCF7	MWDLbY5ie2ViQYPzZZk>	NWTFbW9UPSEQvF2=	MWqyOEBp	NVvkPHRsTE2VTx?=	NXHoVohTUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=>	NXrLb5ByOjR2MUe1OlY>
MDA-MB-231	MlrPT4lv[XOnIFHzd4F6	MVi1JO69VQ>?	Mnm4NlQhcA>?	MlnHSG1UVw>?	M2TkTGlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC=	Mkn6NlQ1OTd3Nk[=
MDA-MB-231	MkjESpVv[3Srb36gRZN{[Xl?	MoDhNU0yOCEQvF2=	MorjNlQhcA>?	M{fUV2ROW09?	NYnrZ4p4\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl	NHiwenczPDRzN{W2Oi=>
MCF7	MVfGeY5kfGmxbjDBd5NigQ>?	MYSxMVExKM7:TR?=	NF;lNFMzPCCq	MnviSG1UVw>?	M1PDdYRw\XNibn;0JIlv\HWlZTDhdI9xfG:\|aYOgZZN{\XO\|ZXSgZZMhWEGUUDDjcIVifmGpZR?=	NEDj[mQzPDRzN{W2Oi=>
MDA-MB-231	MWLGeY5kfGmxbjDBd5NigQ>?	M3W1XlAvPS1zIN88US=>	MnjzOFghcA>?	MkLRSG1UVw>?	MUXoZZMhdm9iQ3XscEBkgWOuZTDhdpJme3RiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IIP1Zk1IOSCyaHHz[S=>	NVvvemhVOjR2MUe1OlY>
MCF7	NGPlWXJHfW6ldHnvckBCe3OjeR?=	MlLkNE42NTFizszN	NInUTnU1QCCq	NGDCbHRFVVOR	M{DwU4hieyCwbzDD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm	M{f2fVI1PDF5NU[2
697	NXLyTlVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrrTWM2OD1zNEiuN\|ghdk1?	MkiwV2FPT0WU
P12-ICHIKAWA	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIi5d2VKSzVyPUm2MlA1KG6P	M3zYXnNCVkeHUh?=
NB69	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWHJR\|UxRTF4MT64JI5O	M4X4eXNCVkeHUh?=
EoL-1	MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1rFZmlEPTB;MUi3MlI3KG6P	MUXTRW5ITVJ?
BHT-101	M2\4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4LCWWlEPTB;MUm4MlI2KG6P	MVzTRW5ITVJ?
SK-NEP-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrxRVFKSzVyPUKyNE4xOiCwTR?=	NVTHUlFYW0GQR1XS
MHH-NB-11	M1S0WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTJ{MD6xPUBvVQ>?	NF\KVFRUSU6JRWK=
AsPC-1	MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PqO2lEPTB;MkWyMlU{KG6P	MVPTRW5ITVJ?
ES1	NX\DO4FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\PTHdKSzVyPUK1Ok4zPSCwTR?=	Mo[4V2FPT0WU
LAMA-84	NF65SJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLzTWM2OD1{NUiuNVkhdk1?	MljWV2FPT0WU
MOLT-16	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVv5O2s1UUN3ME2yOVgvPDlibl2=	MXzTRW5ITVJ?
ES7	NHTCTIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\HPZFKSzVyPUK3N{4xQSCwTR?=	NYrtVZRxW0GQR1XS
KY821	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfuTllKSzVyPUOxOE4yKG6P	MUfTRW5ITVJ?
RT-112	NHXQOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmDWTWM2OD1\|MkGuNFUhdk1?	M4\yRXNCVkeHUh?=
HL-60	NFHR[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITMV2NKSzVyPUO0NE43PiCwTR?=	MmXZV2FPT0WU
MOLT-4	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\vS3VKSzVyPUO0OU4yOyCwTR?=	NHL2NWhUSU6JRWK=
KARPAS-45	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTN5Nj6xOkBvVQ>?	MoHVV2FPT0WU
SK-N-AS	M3\EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nWU2lEPTB;M{i3Mlg{KG6P	M{XES3NCVkeHUh?=
CTB-1	M1nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGOxSmJKSzVyPUSwOU4xOiCwTR?=	NVzJcIpZW0GQR1XS
NKM-1	NX;WT5U4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTRzMT64PUBvVQ>?	MkDYV2FPT0WU
HTC-C3	M2CxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnH6TWM2OD12M{KuPVUhdk1?	MnnMV2FPT0WU
BE-13	NULocnFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HrNWlEPTB;NES0MlI4KG6P	NYnqXJNRW0GQR1XS
KOSC-2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHmTWM2OD12Nk[uPUBvVQ>?	NXK3R4VbW0GQR1XS
NB14	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mln3TWM2OD12OEOuOVghdk1?	MoHYV2FPT0WU
CAL-27	NYG5eFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWm1OmIzUUN3ME20PVQvPTlibl2=	MWPTRW5ITVJ?
H9	MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUX5[YRrUUN3ME20PVUvPDNibl2=	M3Hac3NCVkeHUh?=
RS4-11	MknyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTRTWM2OD13MESuO\|Mhdk1?	M2DJVHNCVkeHUh?=
PA-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzDTWM2OD13MEmuPFYhdk1?	MkTKV2FPT0WU
MV-4-11	M33tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTVzMz64OUBvVQ>?	MWHTRW5ITVJ?
OS-RC-2	NID0cJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPTbnhKSzVyPUWyNU43OiCwTR?=	MVTTRW5ITVJ?
RPMI-8226	NHfaeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWey[ol6UUN3ME21NlYvQDZibl2=	NIjlbZFUSU6JRWK=
HGC-27	M1LHR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTV4ND65PUBvVQ>?	MV;TRW5ITVJ?
CHP-212	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTV7Mz61PUBvVQ>?	MV\TRW5ITVJ?
NB10	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIW3cIVKSzVyPUW5PU4yQCCwTR?=	NFvObJFUSU6JRWK=
HH	Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfE[YFlUUN3ME21PVkvPDNibl2=	NGnqeo5USU6JRWK=
EW-16	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XX[2lEPTB;NkCzMlUzKG6P	MXjTRW5ITVJ?
ES8	NEW5[2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjF[YlKSzVyPU[wOU4zOSCwTR?=	MYXTRW5ITVJ?
HAL-01	M4Ps[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzRTWM2OD14MEWuOlchdk1?	NIeyW41USU6JRWK=
A204	M3Syd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX2RZJKSzVyPU[zN{46OSCwTR?=	MXjTRW5ITVJ?
MHH-PREB-1	M1T0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrVTWM2OD14M{[uPVkhdk1?	M2fmenNCVkeHUh?=
EM-2	NGD1e4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfvfpViUUN3ME22OVAvPjRibl2=	MYrTRW5ITVJ?
BV-173	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjsNGdLUUN3ME22OVIvPDhibl2=	Mn\OV2FPT0WU
ONS-76	NWe2R2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvF[ZhFUUN3ME22O\|cvQDJibl2=	M3uybnNCVkeHUh?=
KM-H2	M3PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLmN5ViUUN3ME22PVUvPTRibl2=	M4rDc3NCVkeHUh?=
D-263MG	MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPRTWM2OD15MUeuNVIhdk1?	MkTmV2FPT0WU
ES3	NUPsRpRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTd{OD65N{BvVQ>?	MY\TRW5ITVJ?
VA-ES-BJ	Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTd\|Mj6yO{BvVQ>?	MXHTRW5ITVJ?
NBsusSR	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2LZXmlEPTB;N{SyMlk6KG6P	MYDTRW5ITVJ?
NCI-H520	NFXaRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlT5TWM2OD15NE[uOVIhdk1?	MoToV2FPT0WU
ES5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFvnTYRKSzVyPUe1Nk45KG6P	MmrtV2FPT0WU
T-24	NF7EO4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTpTWM2OD15N{iuO\|Ehdk1?	NFHUeXlUSU6JRWK=
SW962	M{\kNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVuxXHpTUUN3ME24NFgvPjNibl2=	NH3STZNUSU6JRWK=
EW-3	M4Djbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jiO2lEPTB;OEC4Mlc3KG6P	M3z1XHNCVkeHUh?=
RXF393	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRThzMj63PUBvVQ>?	NGjR[o5USU6JRWK=
U251	NYHkRZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\aTWM2OD16MUOuPFghdk1?	NH;KW5VUSU6JRWK=
CAMA-1	NFTMOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDH[3lKSzVyPUizN{46PCCwTR?=	NGLzfHlUSU6JRWK=
JVM-3	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLIRXpKSzVyPUi1NU44QCCwTR?=	MULTRW5ITVJ?
COLO-800	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2TDNWlEPTB;OEm3Mlc5KG6P	MmixV2FPT0WU
OVCAR-5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfadIMzUUN3ME25NFAvOSCwTR?=	NYH1bItmW0GQR1XS
LB1047-RCC	NWDuTGozT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2T4[WlEPTB;OUK3MlU3KG6P	NVXh[W5mW0GQR1XS
SW954	NIHNZ2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2njfGlEPTB;OUK5MlQyKG6P	Mm\YV2FPT0WU
J-RT3-T3-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlPQTWM2OD17M{[uNFYhdk1?	M3PSZ3NCVkeHUh?=
Mewo	M3r2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml:wTWM2OD17M{[uOkBvVQ>?	MUnTRW5ITVJ?
NCI-H1770	M4PaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3r6UGlEPTB;OUSwMlU2KG6P	MkLZV2FPT0WU
HO-1-N-1	NH:zcHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17wcWlEPTB;OU[yMlgyKG6P	M3HCe3NCVkeHUh?=
HSC-3	M4nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTZTWM2OD17Nk[uOFghdk1?	NYDIdIQ5W0GQR1XS
TYK-nu	M3XtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILCe5VKSzVyPUm5PE4zPSCwTR?=	MkXRV2FPT0WU
KYSE-150	NWLSZmZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVjiclFoUUN3ME2xMlAxODd4IN88US=>	M4LsdnNCVkeHUh?=
SN12C	NXGyWXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7vTWM2OD1zLkCwPFc2KM7:TR?=	NVy4SIN4W0GQR1XS
MOLT-13	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFwMEG0NlEh\|ryP	NHLJe4pUSU6JRWK=
TE-11	M2O3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjLb2hKSzVyPUGuNFQ5OTJizszN	M4W0SnNCVkeHUh?=
DB	NVPLbnlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTFwMEeyO\|Mh\|ryP	NFfXdIdUSU6JRWK=
CAL-39	NETJdmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mk\BTWM2OD1zLkC3OVIzKM7:TR?=	NWLRcpRQW0GQR1XS
A3-KAW	M{XXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLSZ\|BKSzVyPUGuNFg1ODhizszN	NV72bYZMW0GQR1XS
CHP-134	NU\YcFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVnTVXp{UUN3ME2xMlEyQDB5IN88US=>	NUjSfVdyW0GQR1XS
TGW	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjRVY1KSzVyPUGuNVI{QTVizszN	M33FenNCVkeHUh?=
QIMR-WIL	NFW0OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTmTWM2OD1zLkGzNVM1KM7:TR?=	MnnuV2FPT0WU
NCI-SNU-1	NVnlfmFRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF7MdJVKSzVyPUGuNVY{PTRizszN	MVvTRW5ITVJ?
CGTH-W-1	NVryfYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHnZ[HJKSzVyPUGuNVcyQDZizszN	NIjzVYVUSU6JRWK=
MHH-ES-1	NHzE[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVmyOXRUUUN3ME2xMlE4QTh4IN88US=>	MX3TRW5ITVJ?
LB2241-RCC	NV;5UmEyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzrfYRKUUN3ME2xMlE5PjJizszN	NGWyfZFUSU6JRWK=
ML-2	MkjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPNfWpKSzVyPUGuNlA4OzRizszN	MXXTRW5ITVJ?
COR-L23	M{jJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{i1Z2lEPTB;MT6yNlk{OyEQvF2=	MknRV2FPT0WU
BFTC-905	MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUficnROUUN3ME2xMlI1OjZ5IN88US=>	M3\PVHNCVkeHUh?=
Hs-578-T	NHr2UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1r4bmlEPTB;MT6yOVgyPyEQvF2=	M1zsXHNCVkeHUh?=
KG-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXHc25KSzVyPUGuNlY3QDZizszN	NU\rWm9zW0GQR1XS
HEL	NVHKNWZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3j1dGlEPTB;MT6yPVM{QCEQvF2=	M3G4[nNCVkeHUh?=
A549	NIPYN3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2DUWWlEPTB;MT6yPVM6QSEQvF2=	NXTxWFAzW0GQR1XS
COLO-741	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\JTGlEPTB;MT6zNlA5QSEQvF2=	NHTyRmRUSU6JRWK=
PC-3	MlG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFXDRVVKSzVyPUGuN\|UzOjFizszN	NUHBRVdEW0GQR1XS
HOS	NITWTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml3PTWM2OD1zLkO1Nlk3KM7:TR?=	MWPTRW5ITVJ?
HT-1080	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nW[GlEPTB;MT6zO\|UyQSEQvF2=	NHHUPZZUSU6JRWK=
TE-8	NYXHPXJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVq4b4pUUUN3ME2xMlQyPzd2IN88US=>	M1jtN3NCVkeHUh?=
BHY	NYTtS5B4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTFwNE[5NlMh\|ryP	MVrTRW5ITVJ?
BB65-RCC	NHHPVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTFwNUC1Nlgh\|ryP	M{Lyc3NCVkeHUh?=
HN	MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTFwNUSwO\|Eh\|ryP	M4LXU3NCVkeHUh?=
NCI-H441	NEnsWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXLJR\|UxRTFwNUS5NFch\|ryP	MmDCV2FPT0WU
RPMI-8866	MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnnuTWM2OD1zLkW4OVA4KM7:TR?=	NUiwbXUyW0GQR1XS
CAL-62	NFi2NFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTFwNkC4OlIh\|ryP	NHz6RVNUSU6JRWK=
MG-63	MlvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvNeoxKSzVyPUGuOlE5OTNizszN	Ml3zV2FPT0WU
SK-LU-1	NUTscppNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTFwNkKxOVIh\|ryP	NWHjXIxKW0GQR1XS
BCPAP	NGr0[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPBUHJDUUN3ME2xMlY3PDV5IN88US=>	MYXTRW5ITVJ?
22RV1	M2PsRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkW3TWM2OD1zLk[3PFQ{KM7:TR?=	MYfTRW5ITVJ?
T47D	NYHMbYJZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7L[pJrUUN3ME2xMlY5ODZzIN88US=>	NFPGc4dUSU6JRWK=
MSTO-211H	NILZenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVPHOIhQUUN3ME2xMlY6PjB\|IN88US=>	Mm\6V2FPT0WU
DEL	M1:xSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTNTWM2OD1zLkewNlc{KM7:TR?=	NVrsd5QxW0GQR1XS
H4	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\PTHZPUUN3ME2xMlc{OjF{IN88US=>	M{H4fHNCVkeHUh?=
CAL-51	M1\D[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXwW5F[UUN3ME2xMlc1QDV3IN88US=>	NVj6ZnNrW0GQR1XS
ABC-1	NHLuVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH[3b\|VKSzVyPUGuO\|g2QDJizszN	Mlv0V2FPT0WU
MZ2-MEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDDPVRLUUN3ME2xMlc6PTR{IN88US=>	NY\jVmxnW0GQR1XS
YKG-1	NIDIe3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzKSJJKSzVyPUGuPFExPjFizszN	Mkj2V2FPT0WU
KM12	NHn0PXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPSTWM2OD1zLkixOlAzKM7:TR?=	MmfoV2FPT0WU
L-363	NXXidWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTFwOEe0NVIh\|ryP	NFPoW5pUSU6JRWK=
KU812	NIXYRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\STWM2OD1zLki5NlgzKM7:TR?=	NWX3TYpKW0GQR1XS
LOXIMVI	M4HtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTFwOUGyNlgh\|ryP	M1HQWHNCVkeHUh?=
G-401	MlfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTFwOUK0Nlgh\|ryP	NYm0d2J1W0GQR1XS
SW780	NGH1NGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLwTWM2OD1zLkm2NlQ3KM7:TR?=	M3q3b3NCVkeHUh?=
SW872	NH3pN3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HySmlEPTB;MT65PFM{KM7:TR?=	NY\OeYZrW0GQR1XS
NB7	M3;UWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3RTWM2OD1zLkm5N\|I{KM7:TR?=	MWPTRW5ITVJ?
T98G	M3POXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1jhV2lEPTB;Mj6wNFY3PiEQvF2=	MoSzV2FPT0WU
SW1710	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmH4TWM2OD1{LkC2PVQ2KM7:TR?=	MWLTRW5ITVJ?
NCI-H1573	M13nTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fmcWlEPTB;Mj6wO\|I6QCEQvF2=	MWTTRW5ITVJ?
KE-37	M2rsXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XJbWlEPTB;Mj6wPFk2OSEQvF2=	NGrkfIFUSU6JRWK=
786-0	NHnQOZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXubYVKSzVyPUKuNVU1OzlizszN	NEjveVdUSU6JRWK=
SAS	MnHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVXJR\|UxRTJwMkCzO\|Qh\|ryP	M3S3SHNCVkeHUh?=
CAL-54	NFe0dZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXvJR\|UxRTJwMkC0NVMh\|ryP	MX3TRW5ITVJ?
SF268	NHewWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\2TWM2OD1{LkKzNVIzKM7:TR?=	NWXZSZdFW0GQR1XS
SW620	NHG4SIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjKVm1KSzVyPUKuNlYyPjlizszN	NGPx[JlUSU6JRWK=
MN-60	NGHaXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEn2dWdKSzVyPUKuN\|ExPiEQvF2=	MVTTRW5ITVJ?
EFO-27	NGfBUmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDP[4FVUUN3ME2yMlMzODV6IN88US=>	MXXTRW5ITVJ?
NCI-H747	NEX6dpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUOwfZdKUUN3ME2yMlMzOTl7IN88US=>	MlHoV2FPT0WU
HCC2218	M1nGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYP6WGlkUUN3ME2yMlM2Ozd2IN88US=>	NXiz[\|E6W0GQR1XS
MIA-PaCa-2	NIjZXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\VTWM2OD1{LkO2OFM4KM7:TR?=	NUL0Oo5OW0GQR1XS
SJSA-1	M4jtUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M120SGlEPTB;Mj6zO\|c6PiEQvF2=	NGjZfGhUSU6JRWK=
RKO	NFTQSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTJwM{i0PVYh\|ryP	M4TJN3NCVkeHUh?=
NB6	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LrTGlEPTB;Mj60NFM4PCEQvF2=	NGTLcIxUSU6JRWK=
ES4	M4fZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\nS\|h3UUN3ME2yMlQ2PDJ{IN88US=>	MUjTRW5ITVJ?
EGI-1	NH3aNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTydI5HUUN3ME2yMlQ3QDh\|IN88US=>	MWjTRW5ITVJ?
CTV-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;Wd41NUUN3ME2yMlUzPzd\|IN88US=>	MVnTRW5ITVJ?
NCI-H1355	M1r0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrYOXBHUUN3ME2yMlU2QTVzIN88US=>	MVLTRW5ITVJ?
GT3TKB	M{DyWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJwNUmxPVkh\|ryP	MWfTRW5ITVJ?
SK-HEP-1	NYDIdmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJwNUmyOlYh\|ryP	M3vSO3NCVkeHUh?=
GAMG	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jqeWlEPTB;Mj61PVM6PCEQvF2=	M1HDd3NCVkeHUh?=
SK-MES-1	NETlVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPJTWM2OD1{Lk[xPFA{KM7:TR?=	NEHXcmNUSU6JRWK=
RO82-W-1	NV7xb\|JST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTTTWM2OD1{Lk[yNFU4KM7:TR?=	M{\KR3NCVkeHUh?=
ECC10	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzuZppXUUN3ME2yMlcxOjB4IN88US=>	NIm2Z\|JUSU6JRWK=
MCF7	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWf2PG82UUN3ME2yMlcyPDZ2IN88US=>	NEnwbnZUSU6JRWK=
D-283MED	NH\2eWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlX6TWM2OD1{LkeyOFMh\|ryP	NHvKd3pUSU6JRWK=
RPMI-7951	M2\kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvS[Y5KSzVyPUKuO\|U3QTRizszN	M4rNbnNCVkeHUh?=
Ramos-2G6-4C10	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUjJR\|UxRTJwN{ewPVkh\|ryP	NFPRcmxUSU6JRWK=
KGN	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnGd3JKSzVyPUKuPFE5QDRizszN	MXvTRW5ITVJ?
NUGC-3	M4GyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTJwOEK1NFUh\|ryP	NVvrSGFCW0GQR1XS
NCI-H292	NXKxcY44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJwOEWwOVMh\|ryP	MVnTRW5ITVJ?
Becker	NUTiendQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlLpTWM2OD1{Lkm1PFMzKM7:TR?=	M3S3NHNCVkeHUh?=
NCI-H1299	MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HERmlEPTB;Mz6wOVI3OyEQvF2=	M3PUUHNCVkeHUh?=
ETK-1	M2\ESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWftVGx1UUN3ME2zMlA2PDNizszN	MVzTRW5ITVJ?
TK10	NIn2VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzuTWM2OD1\|LkKwNVY2KM7:TR?=	NIXPPVBUSU6JRWK=
VMRC-RCZ	NG\WOGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTNwM{[0PFgh\|ryP	NISxV5BUSU6JRWK=
YH-13	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYLJR\|UxRTNwNESwO\|kh\|ryP	NW\3WZp5W0GQR1XS
DU-145	M1KzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfoTWM2OD1\|LkS2NlY6KM7:TR?=	NHjYPFNUSU6JRWK=
SW1088	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTNwNEe0O{DPxE1?	NUPtZ2VlW0GQR1XS
HOP-92	M1jZR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPBZmFSUUN3ME2zMlUxOzR{IN88US=>	NGr4WXFUSU6JRWK=
KP-N-YS	M3T5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTNwNkKxN\|kh\|ryP	NXnk[FVbW0GQR1XS
NCI-H460	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYj4N5l3UUN3ME2zMlY3PzNizszN	MliwV2FPT0WU
U-2-OS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHC[pJKSzVyPUOuO\|I2OzVizszN	Mo\PV2FPT0WU
A101D	M3L3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTNwN{[5N\|Yh\|ryP	MXPTRW5ITVJ?
MDA-MB-231	NITOVoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYHTe3d{UUN3ME2zMlgyQTVzIN88US=>	NVXQ[\|NTW0GQR1XS
IST-MES1	MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHySm9KSzVyPUOuPFMzKM7:TR?=	MoO4V2FPT0WU
COR-L105	NUTwb4JUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mof4TWM2OD12LkCxPEDPxE1?	MlzHV2FPT0WU
NCI-H1437	M1XsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTRwMEKzNFIh\|ryP	NXf1OnN[W0GQR1XS
CAL-85-1	NULJdm86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnsTWM2OD12LkCyOFYyKM7:TR?=	NGjsWWNUSU6JRWK=
MZ1-PC	NXHMdmwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M17ETWlEPTB;ND6xPFU2PiEQvF2=	NWOybpFPW0GQR1XS
VM-CUB-1	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHezO3dKSzVyPUSuN\|EzQDRizszN	Mmm3V2FPT0WU
CHL-1	MkPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoTpTWM2OD12LkOyNVY6KM7:TR?=	NFj5cFJUSU6JRWK=
MDA-MB-361	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTRwM{OxOVMh\|ryP	NFWwVphUSU6JRWK=
NCI-H661	MkjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XWXmlEPTB;ND61NFA6OiEQvF2=	MlfmV2FPT0WU
EW-11	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYizc2tvUUN3ME20MlUzOjNzIN88US=>	MmjOV2FPT0WU
BEN	NXPZcItCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2G3R2lEPTB;ND61NlgyPSEQvF2=	NF\RWmNUSU6JRWK=
BFTC-909	NG\lXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;rOGJHUUN3ME20MlU3Ojd3IN88US=>	MXfTRW5ITVJ?
NCI-H2087	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDyTWM2OD12LkW4NVY1KM7:TR?=	MnPRV2FPT0WU
RVH-421	M{jFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13YTWlEPTB;ND62OlY6KM7:TR?=	MoTWV2FPT0WU
P30-OHK	NWPxRYc{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITJ[HBKSzVyPUSuOlgxODhizszN	MmLTV2FPT0WU
NCI-H28	M17tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX31SFdXUUN3ME20MlgyPjZzIN88US=>	M2fjfXNCVkeHUh?=
ES6	NETxfoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHz4T2ZKSzVyPUSuPFMxOTZizszN	M3Hlc3NCVkeHUh?=
769-P	NYK3[IU5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTRwOEW5NlYh\|ryP	MV;TRW5ITVJ?
OE33	NGD2fHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDzWFFmUUN3ME20Mlg5OTZzIN88US=>	Mn3VV2FPT0WU
SW982	NGT5UGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrpWHNKSzVyPUSuPVUxPjFizszN	Mmm3V2FPT0WU
A388	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXRNZNKSzVyPUWuNFI6QDNizszN	MX\TRW5ITVJ?
TI-73	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTVwME[xPVQh\|ryP	NUnlVGxiW0GQR1XS
HCT-116	NITSTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnK2TWM2OD13LkC5PFg6KM7:TR?=	NUW3[plFW0GQR1XS
HuP-T3	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlH5TWM2OD13LkG4O\|A6KM7:TR?=	NHThUFNUSU6JRWK=
G-402	M{n0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVLJR\|UxRTVwMUm0NVYh\|ryP	MV\TRW5ITVJ?
NCI-H1792	NULWU2ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH\qS4xKSzVyPUWuNlQ3OjJizszN	MUTTRW5ITVJ?
NCI-H209	NVXiTok1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEXic4VKSzVyPUWuNlU6PDJizszN	NITUTVNUSU6JRWK=
NCI-H1650	NF\pRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;0WlhNUUN3ME21MlMxPjN2IN88US=>	MY\TRW5ITVJ?
LCLC-97TM1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTVwM{G4NFgh\|ryP	NUmxT5UyW0GQR1XS
S-117	NG\JbVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTVwM{[5O\|Yh\|ryP	Mn7UV2FPT0WU
GI-ME-N	NGnMfVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVTNS5YyUUN3ME21MlM6PjhzIN88US=>	MmLyV2FPT0WU
NCI-H2122	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nRT2lEPTB;NT60PVM6PyEQvF2=	M1\QN3NCVkeHUh?=
NCI-H1793	MnPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUDqUZdIUUN3ME21MlY4PTl\|IN88US=>	MXrTRW5ITVJ?
C2BBe1	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLETWM2OD13LkewNFg5KM7:TR?=	MY\TRW5ITVJ?
TE-12	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nUU2lEPTB;NT64NFU2PiEQvF2=	NIPzd5ZUSU6JRWK=
LCLC-103H	M1vCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Moj4TWM2OD13LkmxO{DPxE1?	NF;xbXVUSU6JRWK=
A673	NYTRTmwxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmjnTWM2OD13LkmxPVMzKM7:TR?=	NGXZSo5USU6JRWK=
BB30-HNC	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPDVpoyUUN3ME21Mlk5OzZizszN	MlXXV2FPT0WU
SF295	M3v3WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPNTFBKSzVyPU[uNFA1OjJizszN	M2HQVHNCVkeHUh?=
KU-19-19	M3Po[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTZwMEG3N\|Eh\|ryP	MWjTRW5ITVJ?
CFPAC-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlvMTWM2OD14LkC0OFQ{KM7:TR?=	NVPYeFRvW0GQR1XS
LoVo	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HLTmlEPTB;Nj6wOVA3OyEQvF2=	MX7TRW5ITVJ?
8505C	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MonVTWM2OD14LkC3OVc{KM7:TR?=	MYHTRW5ITVJ?
GMS-10	NH\2e2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjaOJNKSzVyPU[uNVUxODJizszN	NInMZ5NUSU6JRWK=
Ca9-22	NUfD[5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYjQbYVjUUN3ME22MlE3PzFizszN	MmfEV2FPT0WU
DOK	M{[1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTZwMkKwO\|Ih\|ryP	MlPEV2FPT0WU
FADU	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWK4cWZ4UUN3ME22MlI3ODN7IN88US=>	NV;aXFliW0GQR1XS
BxPC-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fINWlEPTB;Nj6yO\|MzKM7:TR?=	NFjBNZlUSU6JRWK=
CAL-33	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLjWZFKSzVyPU[uNlkzODFizszN	M4fCSHNCVkeHUh?=
SHP-77	Mk\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIexWY9KSzVyPU[uN\|E2OTJizszN	MoXjV2FPT0WU
LXF-289	NGLHTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV3IWYZWUUN3ME22MlM{PDV3IN88US=>	MmCyV2FPT0WU
GB-1	MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTZwM{iyJO69VQ>?	NHrq[3VUSU6JRWK=
KS-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUPBO5o2UUN3ME22MlM5PDR5IN88US=>	NU\GSGtrW0GQR1XS
D-502MG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHfRRXdKSzVyPU[uOFI{PzZizszN	NHvINJVUSU6JRWK=
LAN-6	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\TVZNKSzVyPU[uOVExOjNizszN	M{nVcnNCVkeHUh?=
H-EMC-SS	M1vBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWPJR\|UxRTZwNU[xOFch\|ryP	NIHiOXdUSU6JRWK=
LC-2-ad	MmXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPSTWM2OD14Lk[wNFc3KM7:TR?=	NYPrVoxbW0GQR1XS
NCI-H1693	NXr0PFF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHsTWM2OD14Lk[yNlE2KM7:TR?=	M2e5PHNCVkeHUh?=
SK-N-FI	M4S2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M16zPWlEPTB;Nj63OVA1PCEQvF2=	NVvjcHRXW0GQR1XS
D-423MG	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfjeJU5UUN3ME22Mlc3OTF5IN88US=>	M{S4XHNCVkeHUh?=
KNS-42	M1TKO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTZwN{ixPVch\|ryP	Ml3EV2FPT0WU
GCT	NFm5OFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTZwOUO4JO69VQ>?	MoLEV2FPT0WU
DSH1	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTlTWM2OD15LkC2N\|Mh\|ryP	NHvVSnVUSU6JRWK=
D-247MG	M3:2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPXTWM2OD15LkC3PFgyKM7:TR?=	NF2wRWVUSU6JRWK=
NCI-SNU-5	MnjMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\Yc2ZKSzVyPUeuNVg{PzFizszN	M2PBSXNCVkeHUh?=
TE-6	NWO3bXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\mTWlEPTB;Nz6yNFYxOSEQvF2=	NVzreGRoW0GQR1XS
NOMO-1	MljaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTdwMkKxNlch\|ryP	MoXQV2FPT0WU
NB17	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mki4TWM2OD15LkOwN\|A6KM7:TR?=	MXfTRW5ITVJ?
EW-22	MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPnTWM2OD15LkO0N\|Q5KM7:TR?=	MV\TRW5ITVJ?
EW-13	M1fh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUXJR\|UxRTdwM{WxOlIh\|ryP	NFPDZpZUSU6JRWK=
DOHH-2	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXpZ4piUUN3ME23MlQ1ODJizszN	MnrSV2FPT0WU
TGBC1TKB	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIHDVpVKSzVyPUeuOFk5QTlizszN	MnTYV2FPT0WU
GR-ST	MnPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPWSG5CUUN3ME23MlUzPTl2IN88US=>	MXTTRW5ITVJ?
KYSE-520	NH75cINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXiTWM2OD15LkW1OVE2KM7:TR?=	NHjmSm9USU6JRWK=
CAPAN-1	MoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTdwNUm1NUDPxE1?	MlTVV2FPT0WU
HCE-4	NHTWWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHqTmdKSzVyPUeuOlIzPzlizszN	MVLTRW5ITVJ?
MLMA	NV7xRVhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn71TWM2OD15Lk[yPVU4KM7:TR?=	M1e2N3NCVkeHUh?=
HT-144	MkLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGKxfJdKSzVyPUeuOlU{PjhizszN	NH3CcJRUSU6JRWK=
KYSE-180	NXTWN3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTdwN{GxOlkh\|ryP	MnfRV2FPT0WU
TE-5	NEnZO\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4fyXGlEPTB;Nz65OVk4OSEQvF2=	NYi4NIR4W0GQR1XS
IGROV-1	NXHaOJRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jPW2lEPTB;Nz65PFU2OSEQvF2=	NHqzUGFUSU6JRWK=
NCI-H1581	MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFriSYlKSzVyPUiuNFEzKM7:TR?=	MnG1V2FPT0WU
SW1990	NG\rV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTqWIp1UUN3ME24MlA1PjV7IN88US=>	MYHTRW5ITVJ?
EFM-19	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDGRWRSUUN3ME24MlA5PTR3IN88US=>	NYjZfIZLW0GQR1XS
OGR-1	M4Htfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRThwNEOwNlMh\|ryP	Mn;qV2FPT0WU
U-118-MG	NXnZbmZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvCSpBKSzVyPUiuOFM1PjNizszN	NIX3NmpUSU6JRWK=
SK-OV-3	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPqfVIzUUN3ME24MlQ3PzZ3IN88US=>	MmD5V2FPT0WU
KNS-62	NHj6eXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n5b2lEPTB;OD61NVc3OSEQvF2=	NF7WZZNUSU6JRWK=
GOTO	MmO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEDPfWdKSzVyPUiuOVc3OzVizszN	M{DMdXNCVkeHUh?=
8305C	MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvBTWM2OD16LkewOFg1KM7:TR?=	MWfTRW5ITVJ?
RPMI-2650	M165V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLiTWM2OD16LkexPVU2KM7:TR?=	MVPTRW5ITVJ?
NEC8	M13mfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7kfHVKSzVyPUiuO\|Q{ODdizszN	M{DzZXNCVkeHUh?=
KYSE-450	M1rWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvhWmNKSzVyPUiuPFY2PDhizszN	NFThOWFUSU6JRWK=
RMG-I	NIDQRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLETWM2OD17LkG0NFU5KM7:TR?=	MoW2V2FPT0WU
CAKI-1	MoXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTlwM{G5O\|kh\|ryP	NUjHOmF6W0GQR1XS
KYSE-510	NIG3R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4CxU2lEPTB;OT6zOVc4QCEQvF2=	NVzs[VdmW0GQR1XS
A4-Fuk	NIPyeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTlwM{[3NFEh\|ryP	MX;TRW5ITVJ?
AN3-CA	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4THXmlEPTB;OT60OVQ1PCEQvF2=	M1roU3NCVkeHUh?=
SK-N-DZ	NF;Zd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MofGTWM2OD17LkeyPFQ6KM7:TR?=	MnXNV2FPT0WU
HSC-2	M{[zXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGHkcWdKSzVyPUmuO\|Y3OjlizszN	Mnq4V2FPT0WU
EW-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTlwN{mzOlkh\|ryP	Ml\wV2FPT0WU
D-566MG	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTSemRWUUN3ME25Mlg{PjZ2IN88US=>	NVjqOGp4W0GQR1XS
COLO-792	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTlwOUi3OFYh\|ryP	NUns[oFvW0GQR1XS
TE-10	NFvHWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTSOmp4UUN3ME2xNE4xOzl4IN88US=>	M4jMeXNCVkeHUh?=
NCI-H650	NWXyUFl[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f6RmlEPTB;MUCuOFI5PiEQvF2=	NFW3e2RUSU6JRWK=
U-266	NG[1XlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j3OGlEPTB;MUCuOFU2KM7:TR?=	Mlm5V2FPT0WU
Detroit562	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe2NmZKSzVyPUGxMlA2OTVizszN	MVjTRW5ITVJ?
NH-12	M2n0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnJd3UxUUN3ME2xNU4yPDR4IN88US=>	NEC4WnBUSU6JRWK=
CO-314	M1nHT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGrvRWdKSzVyPUGxMlI5PDJizszN	MXfTRW5ITVJ?
IST-MEL1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnkTWM2OD1zMT61N\|I{KM7:TR?=	MXzTRW5ITVJ?
KNS-81-FD	M2jhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDlRphEUUN3ME2xNU42PTJ5IN88US=>	NYT3VZdXW0GQR1XS
SW1463	NXvKdodET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnrkTWM2OD1zMT61PVg6KM7:TR?=	M{LZbXNCVkeHUh?=
NCI-H23	NGO5epZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzpPXNEUUN3ME2xNU43PTV{IN88US=>	NY[zSpF2W0GQR1XS
SK-MEL-2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFPEcJZKSzVyPUGxMlcyQTdizszN	M4PwXXNCVkeHUh?=
NB13	MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWfBWmVwUUN3ME2xNk4yPDl3IN88US=>	MnnZV2FPT0WU
Daoy	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTF{LkK4OVYh\|ryP	MoPvV2FPT0WU
NCI-H1623	MoDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1\1[mlEPTB;MUKuN\|gxOSEQvF2=	NVTQNoJ[W0GQR1XS
NMC-G1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnuwTWM2OD1zMj63NVch\|ryP	NX2weFd[W0GQR1XS
DK-MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWLkTog2UUN3ME2xNk46PDh{IN88US=>	M4fVRnNCVkeHUh?=
TCCSUP	M2jxdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mni0TWM2OD1zMz6xNlg1KM7:TR?=	Mn\6V2FPT0WU
SCC-15	NYDCRpA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\VeW9PUUN3ME2xN{4zPjVzIN88US=>	MYfTRW5ITVJ?
NOS-1	MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M176N2lEPTB;MUOuNlg6OyEQvF2=	NFXpOlVUSU6JRWK=
RH-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NY\sNng6UUN3ME2xN{4{ODN5IN88US=>	M3;udHNCVkeHUh?=
SK-MEL-3	MoW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkTvTWM2OD1zMz6zO\|I5KM7:TR?=	M3T3eHNCVkeHUh?=
NB5	M3PwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7iRXdjUUN3ME2xN{41ODZ5IN88US=>	M2LPdXNCVkeHUh?=
SNU-387	NUC5c25LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHrSVW1KSzVyPUGzMlUxPzJizszN	M4ThUXNCVkeHUh?=
CAL-120	MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV[0dVYyUUN3ME2xN{43PzF6IN88US=>	NIPQe3pUSU6JRWK=
Mo-T	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTF\|LkewO{DPxE1?	MnnxV2FPT0WU
LNCaP-Clone-FGC	NFLW[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIK5doRKSzVyPUGzMlc6QTJizszN	NX;pW\|ZxW0GQR1XS
CAN	NIT5[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HzdGlEPTB;MUSuNFI5QCEQvF2=	MVrTRW5ITVJ?
SK-MEL-30	NVrkR48yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnm0TWM2OD1zND6wOlMh\|ryP	Mly5V2FPT0WU
COLO-678	NHLa[HpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3G0dWlEPTB;MUSuNFgzOiEQvF2=	MXzTRW5ITVJ?
SCC-9	MnKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NG\rNWlKSzVyPUG0MlExOjFizszN	M3OzW3NCVkeHUh?=
KINGS-1	NVz1W\|dYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUP1[YxvUUN3ME2xOE4yPDB{IN88US=>	Ml;GV2FPT0WU
SL-513	Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTF2LkG4O{DPxE1?	NWL6T45TW0GQR1XS
HLE	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFLGOW9KSzVyPUG0MlM5PTJizszN	M1f0OXNCVkeHUh?=
SW1573	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTqVpZXUUN3ME2xOE41PDN3IN88US=>	NGTlSJBUSU6JRWK=
KYSE-140	NHLFfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1yzemlEPTB;MUSuOlMzPyEQvF2=	NFfhdIFUSU6JRWK=
SK-PN-DW	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\iNI9mUUN3ME2xOE45ODBzIN88US=>	NUP4cnFDW0GQR1XS
A253	NHLL[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TufmlEPTB;MUWuNFYzPSEQvF2=	MY\TRW5ITVJ?
CAL-12T	M{XFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3WxT2lEPTB;MUWuOFY3OiEQvF2=	Mke1V2FPT0WU
COLO-679	M3HHUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;nRXVKSzVyPUG1Mlc3QDNizszN	MX;TRW5ITVJ?
UACC-257	NF3zU4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYf0bY4xUUN3ME2xOk4yOjBzIN88US=>	Mli3V2FPT0WU
U-87-MG	NUnPSVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjXUZpKSzVyPUG2MlM2OjNizszN	NFG4WFFUSU6JRWK=
HCC1806	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF4LkewO\|Eh\|ryP	MoDVV2FPT0WU
NCI-H2170	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTF5LkK0OFgh\|ryP	NVnQd\|lDW0GQR1XS
AGS	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfuXFZKSzVyPUG3MlM5ODhizszN	MoPNV2FPT0WU
MEL-HO	MlzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlPoTWM2OD1zNz63OVA{KM7:TR?=	M3y2b3NCVkeHUh?=
SW48	NGfUV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUDJR\|UxRTF5Lke3NVYh\|ryP	MkOxV2FPT0WU
HuP-T4	NFS4W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTHTWM2OD1zOD6wNlA3KM7:TR?=	M4DBN3NCVkeHUh?=
NCI-H720	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknQTWM2OD1zOD6xOFAzKM7:TR?=	MmPWV2FPT0WU
RCC10RGB	NXrwUZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLTTWM2OD1zOD6xOlk4KM7:TR?=	NW[5cm9PW0GQR1XS
HD-MY-Z	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTF6LkKyOVQh\|ryP	M4W2NXNCVkeHUh?=
A427	M3jUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;sTWlEPTB;MUiuOVA6PCEQvF2=	NGXJXoJUSU6JRWK=
HCC2998	NGP1c\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4nPUWlEPTB;MUiuOlA2OSEQvF2=	MmOzV2FPT0WU
EPLC-272H	NVL2cWxJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLtW3pKSzVyPUG5MlA1OzRizszN	NX3XcohjW0GQR1XS
C32	M1y1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXhTWM2OD1zOT6wOFUh\|ryP	Mm\xV2FPT0WU
UMC-11	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknnTWM2OD1zOT6yNVI{KM7:TR?=	NIDnVHVUSU6JRWK=
CaR-1	M3[ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXrTWM2OD1zOT62PFA1KM7:TR?=	NH20NnNUSU6JRWK=
KYSE-410	NH3vXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnXoTWM2OD1zOT65NVM6KM7:TR?=	M4H5XnNCVkeHUh?=
HuCCT1	MoHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml;OTWM2OD1{MD62Nlk1KM7:TR?=	M2nvdnNCVkeHUh?=
LB996-RCC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI[3PGxKSzVyPUKwMlcyPjhizszN	MYnTRW5ITVJ?
KYSE-70	NH7PZ21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXLTWM2OD1{MD64NFU6KM7:TR?=	NWDMO2xOW0GQR1XS
CAL-72	NYXaVHNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnpTWM2OD1{MD65NVUh\|ryP	NH;QR3JUSU6JRWK=
Capan-2	MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\vTWM2OD1{MT6wOFE{KM7:TR?=	NYrzU5R4W0GQR1XS
PANC-08-13	M4rQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{nUXGlEPTB;MkGuNlUyPSEQvF2=	MWPTRW5ITVJ?
SBC-1	NUjG[VZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGT6[nlKSzVyPUKxMlMxQDFizszN	MoHnV2FPT0WU
MFM-223	NV;VUZVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTJzLkOzOFIh\|ryP	NUXXUXU6W0GQR1XS
BB49-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTJzLkW3NVYh\|ryP	MWHTRW5ITVJ?
SH-4	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfKXXFoUUN3ME2yNU43PjF6IN88US=>	NF\Q[lBUSU6JRWK=
HuO9	M{\WWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3OTWM2OD1{MT65PFI2KM7:TR?=	MYXTRW5ITVJ?
AM-38	NWXEcJVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVXJR\|UxRTJ{LkC0PFUh\|ryP	Mn30V2FPT0WU
A431	NX3k[YFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nRXGlEPTB;MkOuNlEyQSEQvF2=	M1zL[XNCVkeHUh?=
YAPC	NH\lV3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTpU4lwUUN3ME2yN{4zPjVzIN88US=>	MlnYV2FPT0WU
LU-139	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJ\|LkS4NFkh\|ryP	NXzEcVdjW0GQR1XS
HEC-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTJ\|LkS5N\|ch\|ryP	NV3YcZhIW0GQR1XS
SCC-25	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmm3TWM2OD1{ND6zNFA3KM7:TR?=	MXvTRW5ITVJ?
HT-29	NG\1[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnX1TWM2OD1{ND6zPFI{KM7:TR?=	NH;qN5hUSU6JRWK=
PC-14	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFf0SmRKSzVyPUK0MlY2PzFizszN	NITqfXJUSU6JRWK=
Calu-6	M3jhZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1KwPWlEPTB;MkWuOVA4OSEQvF2=	M2HMUnNCVkeHUh?=
SJRH30	MlTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVXGN5BCUUN3ME2yOU43PDl4IN88US=>	MkXUV2FPT0WU
ChaGo-K-1	M2[ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI\YSo5KSzVyPUK2MlE3OjlizszN	NYLqS5lVW0GQR1XS
IA-LM	M364Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;sZ2FKSzVyPUK2MlM3PDVizszN	MWPTRW5ITVJ?
GP5d	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTJ4LkS0PVEh\|ryP	NVTH[2RwW0GQR1XS
NCI-H2291	NIHKV3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\h[GlEPTB;Mk[uOlU1OSEQvF2=	MXTTRW5ITVJ?
BALL-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnqxTWM2OD1{Nj65N\|k4KM7:TR?=	MoH3V2FPT0WU
HCC1954	MmTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TNRmlEPTB;Mk[uPVgxQCEQvF2=	MWnTRW5ITVJ?
NCI-H2452	MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrZNGxKSzVyPUK3MlQyPjNizszN	NVrxUWZqW0GQR1XS
LU-99A	M{fHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJ5LkW1PFIh\|ryP	NXPNeG5MW0GQR1XS
NTERA-S-cl-D1	M1vtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7ITWM2OD1{Nz63Nlk6KM7:TR?=	MXnTRW5ITVJ?
PANC-10-05	M2G5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4T4R2lEPTB;MkeuO\|c4PSEQvF2=	NFjIZnpUSU6JRWK=
NCI-H2405	NVrRZ5pVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGLkdplKSzVyPUK3Mlk{QDdizszN	NWfKRpkxW0GQR1XS
MDA-MB-415	NXSyVXRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknYTWM2OD1{OD60NVM4KM7:TR?=	MUPTRW5ITVJ?
NCI-H2342	NGrP[3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnyTWM2OD1{OD61NlgyKM7:TR?=	MUjTRW5ITVJ?
TGBC24TKB	NFuzNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LHVWlEPTB;MkiuO\|EyPyEQvF2=	MmTiV2FPT0WU
LU-134-A	MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnj6TWM2OD1{OD65NlYyKM7:TR?=	NFGzcYVUSU6JRWK=
SCC-4	MlS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fvWGlEPTB;M{GuNFQ6PCEQvF2=	MVPTRW5ITVJ?
Saos-2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fpWWlEPTB;M{GuPVMxPiEQvF2=	M2fTWnNCVkeHUh?=
RERF-LC-MS	MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfVTWM2OD1\|Mj64NlMyKM7:TR?=	M1fsRXNCVkeHUh?=
M14	NFjSSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTDTWM2OD1\|Mj65O\|Y1KM7:TR?=	Moi1V2FPT0WU
HPAF-II	NF3HNXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu2TWM2OD1\|Mz61NFEyKM7:TR?=	NHTEd2JUSU6JRWK=
NCI-H1755	MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfmdVRKSzVyPUO0MlM{ODVizszN	NYjjT5JnW0GQR1XS
D-392MG	NH\pbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\nflc4UUN3ME2zOU45Pjd2IN88US=>	NX;OTY84W0GQR1XS
A704	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYXGUZlmUUN3ME2zOk4xPDJ5IN88US=>	NV\DfGdIW0GQR1XS
CP50-MEL-B	NX3OUVF7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXqbYFKSzVyPUO2MlE6OTFizszN	NWLzVHFCW0GQR1XS
EW-18	NV21PHlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mny0TWM2OD1\|Nj60OVIh\|ryP	MUTTRW5ITVJ?
WM-115	M3zVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPZTWM2OD1\|Nj64NFk6KM7:TR?=	NIHnNJdUSU6JRWK=
LU-65	NWTiUJppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYftfFhpUUN3ME2zO{4yPDF5IN88US=>	Mn;mV2FPT0WU
NCI-H1563	NWjIU2NTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrnVYN4UUN3ME2zO{4zPDh2IN88US=>	MmDNV2FPT0WU
DBTRG-05MG	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3e0N2lEPTB;M{iuNFY6OSEQvF2=	M1PyfHNCVkeHUh?=
NCI-H630	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7UTWM2OD1\|OD60O\|E1KM7:TR?=	NETuV5RUSU6JRWK=
NCI-H1155	NXX2epVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M13qWWlEPTB;M{muNlQzKM7:TR?=	MkS3V2FPT0WU
OVACR-3	M2jRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1z0R2lEPTB;M{muPVE6PSEQvF2=	NVG0NGVrW0GQR1XS
OAW-42	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T6N2lEPTB;NECuOFI2QCEQvF2=	MkP2V2FPT0WU
JVM-2	NVfCZ3lLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmWwTWM2OD12MT6yOFE2KM7:TR?=	MVXTRW5ITVJ?
C3A	NEe5RWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{CwcWlEPTB;NEGuN\|Q1PyEQvF2=	NF7qb3FUSU6JRWK=
HT55	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;xTWM2OD12Mj6yPFQyKM7:TR?=	M{j3WHNCVkeHUh?=
OVCAR-4	MmTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4e4OmlEPTB;NEKuNlk4PCEQvF2=	M3\PXnNCVkeHUh?=
MEG-01	NELVfnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fac2lEPTB;NEKuOFYyPiEQvF2=	M3nGUnNCVkeHUh?=
NCI-H82	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXvJR\|UxRTR\|Lkm4PVIh\|ryP	MVrTRW5ITVJ?
JEG-3	MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTR2Lkm0O{DPxE1?	NITkTZhUSU6JRWK=
BPH-1	MmTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXaOpFOUUN3ME20Ok4{QTl6IN88US=>	MXfTRW5ITVJ?
MPP-89	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13VWGlEPTB;NEeuNlg6QCEQvF2=	M4\uNHNCVkeHUh?=
ALL-PO	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1P4XGlEPTB;NEeuOFE5QCEQvF2=	M1P5cHNCVkeHUh?=
HT	NVvHeHZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1u2R2lEPTB;NEeuOFkzKM7:TR?=	MV\TRW5ITVJ?
NCI-H2347	M1T2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF\wNYZKSzVyPUS4MlA4OTVizszN	M2rJWXNCVkeHUh?=
A2780	MnPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITuUohKSzVyPUS5MlQzOjhizszN	NUDHZlFbW0GQR1XS
KARPAS-299	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zCPWlEPTB;NEmuOVEyQSEQvF2=	MUXTRW5ITVJ?
NCI-H1651	Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITUfIRKSzVyPUS5Mlg5OjFizszN	M2nrdHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	RB1 (pT821) / RB1 (pS780) / RB1 / CDK6 / CCND2 / RUNX1 / ETO; PubMed: 30300583 Cancer Cell Immunoblots showing dose-dependent impact of 72 hr palbociclib treatment on indicated protein levels in Kasumi-1 and SKNO-1 cells. pRb(S807, 811) / CDK4 / CDK6 / PARP; PubMed: 28453226 Mol Oncol Effects of palbociclib on CDK4/6-Rb pathway. HCC cells were treated with different doses of palbociclib for 24 h, and then, the cells were subjected to western blot analysis. CF, cleaved fragment. LC3-I / LC3-II; PubMed: 28453226 Mol Oncol Palbociclib increases LC3-II amount in a dose-dependent manner in HCC cell lines. pAMPKα(T172) / pULK1(S317); PubMed: 28453226 Mol Oncol Dose-dependent response of palbociclib on AMPK-related molecules. HCC cells were treated with different concentrations of palbociclib for 24 h. The phosphorylation of the indicated proteins was determined by western blotting. SMAD2 (pS255); PubMed: 30343527 Cancer Sci T47D cells were treated with indicated concentrations of palbociclib for 24 h to evaluate substrate phosphorylation.	30300583 28453226 30343527
Growth inhibition assay	Cell viability; PubMed: 29670090 Cell Death Dis Cell viability was determined by MTT assays after palbociclib exposure for 2, 4, and 6 days. The cell cycle of SYO-1 and Fuji cells was assessed after exposure to palbociclib (1 µM) for 24 h by flow cytometry analysis.	29670090
Immunofluorescence	SAHF/ATRX; PubMed: 26988987 Cancer Res DAPI staining for senescence-associated heterochromatic foci (SAHF, left panel) and ATRX staining (right panel) in 1205Lu cells +/− palbociclib for 8 days. LC3B; PubMed: 28453226 Mol Oncol LC3B immunofluorescence in palbociclib‐treated Hep3B cells. Arrowheads indicate LC3-positive autophagosomes. Nuclei were counterstained with DAPI (blue).	26988987 28453226
ELISA	PGE2; PubMed: 26540629 Oncotarget The supernatant of control and 7.5 μM palbociclib-treated cells was collected and stored at −80°C. PGE2 secretion was detected using ELISA.	26540629

In vivo

PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse Cdk Assays: A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl₂, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-³²P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-³²P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-³²P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4 °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research: ^[1]	- Collapse Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562 Concentrations: 0.01-1 μM Incubation Time: 24 hours Method: Cells are seeded at 2 × 10⁴ per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [¹⁴C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice. Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0) Dosages: 0-150 mg/kg Administration: Given by gavage (Only for Reference)

References

[4] Katsumi Y, et al. Biochem Biophys Res Commun, 2011, 413(1), 62-68.

- Collapse

Solubility (25°C)

In vitro	Water	30 mg/mL (61.98 mM)
	DMSO	3 mg/mL warmed (6.19 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): Saline For best results, use promptly after mixing.	6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Palbociclib (PD-0332991) HCl SDF

Molecular Weight	483.99
Formula	C₂₄H₂₉N₇O₂.HCl
CAS No.	827022-32-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A
Smiles	Cl.CC(=O)C1=C(C)C2=CN=C(NC3=NC=C(C=C3)N4CCNCC4)N=C2N(C5CCCC5)C1=O

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03870919	Not yet recruiting	Drug: Palbociclib\|Other: locoregional treatment	Breast Cancer Stage IV\|Radiotherapy\|Surgery	UNICANCER\|Pfizer	October 15 2019	Not Applicable
NCT03900884	Not yet recruiting	Drug: Venetoclax\|Drug: Palbociclib\|Drug: Letrozole	Breast Neoplasm Female	Peter MacCallum Cancer Centre Australia	September 2019	Phase 1
NCT03844997	Recruiting	Drug: Palcociclib\|Drug: CPX-351	Acute Myeloid Leukemia\|AML	Aziz Nazha\|Case Comprehensive Cancer Center	May 31 2019	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Most Potent CDK Inhibitor

LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.
CDK Inhibitor in Clinical Trial

Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).
Newest CDK Inhibitor

NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with K_i of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.
SNS-032 (BMS-387032)

SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

Palbociclib (PD-0332991) HCl